Clinical trial
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic…
NCT00019812 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00019812 |
|---|---|
| Title | Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 |
| Official title | Study of Trastuzumab (Herceptin) and Paclitaxel in Patients With HER2-Overexpressing Metastatic Breast Cancer |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, paclitaxel |
| Enrollment | 55 |
| Start date | Aug 1, 1999 |
| Completion | Feb 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: